Anavex Life Sciences Corp (AVXL)

[rx7171]

On appeal no new data can be submitted, only the data previously considered.

The hope is the new rapporteur and partner will have a more open mind to a treatment that clearly leaves the long held bias toward anti-amyloid therapies as the target.

The 30 member CHMP is spoon fed the opinion of the two rapporteurs and I suspect tend to defer to them since they have spent so much time understanding the data.
So the results are mostly a result of two people.

Two fresh sets of eyes and priorities can change the result.
Just like it did when the two Mabs were rejected then passed on appeal.